Anika Therapeutics reports Q4 EPS (3c), consensus 9c

Reports Q4 revenue $30.6M, consensus $29M. Cheryl Blanchard, president and CEO of Anika Therapeutics (ANIK), commented: “Anika executed on our key goals and financial objectives this quarter. We delivered on our guidance for revenue and profit. Strategically, 2024 was a year of significant progress highlighted by our decision to sharpen our focus to our OA Pain Management and Regenerative Solutions products. We are confident the steps we have taken this year will serve to increase the growth profile of Anika for years to come as we’ve demonstrated with our Commercial Channel growing 17% per year over the past three years.”